Events

In 2025, talent development isn’t just a support function, it’s a strategic imperative. As life sciences organizations navigate technological transformation, workforce disruption, and the rise of advanced therapies, the ability to upskill, retain, and mobilize high-performing talent is now mission-critical. LEAP TD: Life Sciences is the only event designed exclusively for senior talent development (TD) leaders in biotech and pharma to rethink how learning, leadership,and workforce planning can drive real business impact. This is not another L AND D expo. It’s a strategic, high-level forum where talent development, training, and L AND D leaders working in life sciences come together to:Design learning interventions that keep pace with AI, automation, and evolving scientific modalities Build…

Delivering Oligonucleotides with Specificity, Mitigating Off-Target Effects, and Improving Cellular Uptake to Target Undruggable Molecules. The Oligonucleotide-based Therapeutics Summit is uniting leaders in RNA chemistry, delivery science, and translational biology to advance oligonucleotides as a pioneering therapeutic class. With multiple approvals, growing clinical validation across diverse indications, and breakthroughs in chemical modifications and delivery platforms, oligonucleotides are no longer a niche field, they’re rapidly becoming the modality of choice for tackling both validated and previously “undruggable” targets. The question is no longer if oligonucleotides will reshape the therapeutic landscape, but how fast. This December in Boston, unite with leading experts from Seca…

Europe is experiencing a renaissance in GPCR-targeted drug discovery. The unprecedented commercial success of GLP-1 receptor agonists in obesity has reignited investment, innovation, and clinical exploration across the GPCR space. With major deals such as Eli Lilly’s $1.3 billion collaboration to advance small-molecule GPCR therapeutics using AI- and ML-powered platforms, momentum is building fast, making 2025 a pivotal year to be part of this rapidly evolving field. Returning as the only meeting dedicated exclusively to GPCR drug discovery and development in Europe, the 2nd Annual GPCR-Targeted Drug Discovery Summit Europe brings together the brightest minds in biopharma to translate this momentum into actionable strategies. From expanding pipelines in cardiometabolic disease, neuroscienc…

2025 marks an exciting phase for covalent drugs, with the field doubling down on de-risked assets and tackling high-value targets in oncology, immunology, and beyond. With MOMA Therapeutics recently dosing their first patient with a covalent Werner helicase inhibitor, and Novartis partnering with covalent pioneer Matchpoint Therapeutics in a $60 million deal, it's clear that the therapeutic potential of covalency is growing. The 3rd Covalent Drug Discovery and Development Summit returns as the premier industry forum for experts to accelerate the discovery, translation and development of covalent drugs, driving the next wave of first- and best-in-class therapeutics against previously undruggable targets. Uniting covalent drug leaders from the likes of Vividion Therapeutics, Pfizer, Revoluti…

We're thrilled to welcome you to the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2025) in Singapore, 9-11 December 2025, our quest to create a brighter future for diabetes care across the region. Our conference is dedicated to fostering a community where experts can come together to share knowledge, insights, and a genuine passion for transforming lives. We're all about customizing strategies for diabetes management that truly resonate with the unique needs of patients in Asia and beyond. Our lineup of speakers and sessions promises to be inspiring, enlightening, and empowering. We're excited to create a space where ideas can flourish, connections can be made, and meaningful change can take root. ATTD-ASIA is not just a conference, but a community of lik…

In this session, Dr. Vladimir Muzykantov will present an in-depth analysis of the current advances and challenges in drug targeting, biomaterials, nanomedicine, drug delivery systems (DDS), intracellular delivery, and biotherapeutics (Bios). Highlights of the presentationBiotherapeutics (Bios) as a new pharmacological class: Discussion of their catalytic precision, biological potency, and delivery challenges within systemic circulation.Delivery challenges and bottlenecks: Exploration of nanoscale targeting requirements, intracellular addressing (cytosol vs nucleus), and barriers to effective biodistribution and clearance.Cognizant vs. Fortuitous Targeting Approaches: Comparison of rational ligand-based targeting versus chance discoveries ("fortuitous homing"), including advantages, limitat…

Kick off 2026 and set the tone for the year at 18th Annual Pre-Filled Syringes and Injectable Drug Devices Conference! Join us in London on the 13th - 15th January 2026 where we will unite leaders and innovators from the device development industry. This highly anticipated conference offers unparalleled opportunities to explore the latest advances in combination product technology, share insights, and foster collaboration across a dynamic three-day program. As part of SAE's leading Injectable Drug Delivery Series, the event features: - Pre-Conference Focus Day: PFS Design for Enhanced Drug Delivery- Two-Day Main Conference: Morning keynote plenaries and afternoon parallel topic streams addressing the industry's most pressing challenges, including:- Large-Volume Drug Delivery Solutions- Sus…

The Pharma and Biotech Patent Litigation Track at the Patent Litigation Europe Summit 2026 is the leading European forum for life sciences IP counsel and litigators to benchmark enforcement strategies, navigate evolving UPC case law, and prepare for the next wave of biosimilar and generic challenges. Taking place on 20–21 January 2026 at the Beurs van Berlage in Amsterdam, the track continues the legacy of the Pharma and Biotech Patent Litigation Summit while introducing a broader cross-sector environment under the newly rebranded Patent Litigation Europe umbrella. This stream remains the anchor event for the life sciences audience, attracting around 600 attendees, with an exceptional 45% in-house counsel ratio from leading pharmaceutical innovators, biotechs, generics and biosimilar devel…

Attend the Marcus Evans 29th Edition Strategic Project & Portfolio Management for Pharma conference taking place in Frankfurt, Germany between 26-28 January and join industry leaders, strategists, and innovators for an exclusive event focused on transforming how portfolios are prioritized, managed, and accelerated across the R&D lifecycle. From strategic portfolio planning and dynamic resource allocation to AI-powered decision support and cross-functional execution, discover the latest approaches driving agility and impact in pharma. Key Topics Include:  Transformative portfolio management approaches using AI Strategic Agility in the Age of AI: Leading Pharma Portfolio from Vision to Execution Bridging the Gap Between Market Objectives and Research Needs Achieving a strategic…

Attend the Marcus Evans 29th Edition Strategic Project & Portfolio Management for Pharma conference taking place in Frankfurt, Germany between 26-28 January and join industry leaders, strategists, and innovators for an exclusive event focused on transforming how portfolios are prioritized, managed, and accelerated across the R&D lifecycle. From strategic portfolio planning and dynamic resource allocation to AI-powered decision support and cross-functional execution, discover the latest approaches driving agility and impact in pharma. Key Topics Include:  Transformative portfolio management approaches using AI Strategic Agility in the Age of AI: Leading Pharma Portfolio from Vision to Execution Bridging the Gap Between Market Objectives and Research Needs Achieving a strategic…

Discover, Develop and Selectively Deliver Highly Stable and Potent RNAi Therapeutics for Targeted and Effective Gene Silencing in Oncology, Rare, Cardiovascular Disorders and Beyond The 7th RNAi-Based Therapeutics Summit is the industry's premier dedicated forum for translating the next wave of siRNA and microRNA drugs from bench to bedside. As the only event uniting the entire RNAi ecosystem from discovery and complex chemistry to clinical development and CMC, this Summit provides an unparalleled platform to tackle the field's most pressing challenge: delivery beyond the liver. This is your unique opportunity to join 80+ senior leaders from pharma and biotech to gain the data-driven insights and high-value connections needed to overcome stability challenges, de-risk clinical translation,…

mRNA is no longer just a headline, it's transforming medicine. From BioNTech's acquisition of CureVac to the EMA's and MHRA's latest guidance on mRNA product development, and even the world's first personalised CRISPR therapy for Baby KJ, the field has reached a new level of stability while opening doors to revolutionary therapeutic and gene editing applications. Returning for its fifth year, the mRNA-Based Therapeutics Summit Europe gives you the insights and connections to turn these breakthroughs into action. The new Gene Editing Focus Day highlights how mRNA enables safer, transient editing strategies, while addressing regulatory and translational challenges. Hear directly from Moderna, AstraZeneca, CybernaX Bio, Avocet Bio, and others about clinical readiness and delivery innovations…

Enabling Rapid Target Selection, Discovery and Rational Design of Degrading and Non-Degrading Molecular Glue to Develop Potent, Selective and Safer Cures for Cancer and Beyond. Molecular glues are leading the charge in the race to drug the previously undruggable, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues, this meeting will provide actionable strategies to accelerate the development of safer, more selective candidates toward the clinic. If you’re looking to lead the way in the…

Returning to Boston for its 9th year, the DDR Inhibitors Summit is the definitive industry forum for drug developers advancing DNA Damage Response (DDR)-targeted therapies. With PARP inhibitors now clinically validated, the field is rapidly evolving to explore novel DDR targets like ATR, CHK1/2, DNA-PK, and WEE1, alongside smarter biomarker strategies and combination approaches. This year's summit is your opportunity to stay ahead of the curve. Across three content-rich days, you'll uncover translational breakthroughs, hear from biotech innovators and academic pioneers, and gain strategic insights to overcome resistance, enhance selectivity, and accelerate clinical success. With the DDR landscape rapidly expanding, now is the time to connect, collaborate, and shape the future of targeted o…

For more than two decades, biopharma has struggled to develop safe and effective non-opioid pain therapies. With Vertex’s recent approval marking a long-awaited breakthrough, the momentum has reached a critical point for bringing non-opioid pain therapeutics to market. Whether advancing NaV-targeting drugs or pursuing novel pain mechanisms, non-opioid therapeutics are now in the clinical spotlight and the next 12 months promise to be transformative. The Non-Opioid Pain Therapeutics Summit provides a dedicated platform to harness that momentum. Attendees will be learning from companies with approvals such as Tonix, exploring late-stage strategies from innovators like Latigo and Algiax, and uncovering discovery breakthroughs from Nocion and Axonis. Join 70+ discovery, preclinical, translatio…

Inspection Readiness 360 unites clinical operations, TMF, quality, and regulatory leaders for two days of expert insights, case studies, and strategies to ensure your organization is inspection-ready in any environment. Date and Time: On Tue, 27 Jan 2026 09:00 - Wed, 28 Jan 2026 17:00 Venue Details: Convene Two Commerce Square, 2001 Market Street, Philadelphia, Pennsylvania, 19103, United States Category: Conferences | Science, Health and Medicine

Discover how AI is transforming medical affairs at the 5th Annual AI in Medical Affairs, taking place January 27-28, 2026, in Philadelphia, PA.Join pharmaceutical, biotech, and medical device leaders to explore real-world AI applications, innovative strategies, and compliance best practices.Engage in expert panels, case studies, and networking to gain actionable insights that enhance content creation, optimize field medical operations, and drive impactful stakeholder engagement. Time: 9:00 AM - 5:00 PM Venue Details: Convene Two Commerce Square, 2001 Market Street, Philadelphia, Pennsylvania, 19103, United States Category: Conferences | Science, Health and Medicine